AdventHealth Cancer Institute
AdventHealth Cancer Institute
Orlando, Florida, United States11 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 | 2026-10-06 | NCT06624085 | |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Endometrial Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, gastric cancer, gastric neoplasm, gonadal disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, metastatic neoplasm, neoplasm, ovarian cancer, ovarian carcinoma, ovarian disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, small cell lung carcinoma, stomach disorder, triple-negative breast carcinoma, uterine disorder | Recruiting | Phase 1 | 2026-10-06 | NCT06586957 | |
| Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-30 | NCT06765109 | |
| A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 3 | 2026-09-25 | NCT06750094 | |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, adenoid cystic carcinoma, benign urinary system neoplasm, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cervix disorder, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, esophageal cancer, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gastric cancer, gastric neoplasm, gastroesophageal junction adenocarcinoma, gonadal disorder, intestinal disorder, kidney cancer, kidney disorder, lung disorder, lung neoplasm, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, melanocytic neoplasm, melanoma, metastatic melanoma, metastatic prostate carcinoma, mouth disorder, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, primitive neuroectodermal tumor, prostate cancer, prostate disorder, rectal disorder, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, salivary gland cancer, salivary gland disorder, sarcoma, skin disorder, skin neoplasm, small cell lung carcinoma, stomach disorder, transitional cell carcinoma, urinary system disorder, urothelial carcinoma, uterine disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-14 | NCT04140526 | |
| Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia | autoimmune hemolytic anemia, warm type | Active, not recruiting | Phase 2 / Phase 3 | 2026-08-31 | NCT04119050 | |
| Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | Adnexal Diseases, DNA Virus Infections, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Infections, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube cancer, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, milker's nodule, neoplasm, ovarian cancer, ovarian disorder, primary peritoneal carcinoma, vaccinia, viral infectious disease | Recruiting | Phase 3 | 2026-08-26 | NCT05281471 | |
| Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors | Advanced Solid Tumor | Recruiting | Phase 1 / Phase 2 | 2026-08-17 | NCT06635785 | |
| A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 2 | 2026-08-06 | NCT06456463 | |
| Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) | Adnexal Diseases, Carcinoma, Ovarian Epithelial, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, carcinoma, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 3 | 2026-07-02 | NCT06819007 | |
| Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy | female reproductive organ cancer, neoplasm | Recruiting | Not stated | 2025-01-29 | NCT04957511 |